Synapse - Works

Results (13087)

Carfilzomib-lenalidomide-dexamethasone versus bortezomib-lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: Results from the prospective, longitudinal, observational CoMMpass study

Meeting Abstract

Landgren, O.; Siegel, D. S.; Auclair, D.; Chari, A.; Boedigheimer, M.; Welliver, T.; Mezzi, K.; Iskander, K.; Jakubowiak, A.
Blood (2018)

Fulltext@MSK | Save

Updated results from the phase 2 CENTAURUS study of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM)

Meeting Abstract

Landgren, O.; Cavo, M.; Chari, A.; Cohen, Y. C.; Spencer, A.; Voorhees, P. M.; Estell, J.; Sandhu, I.; Jenner, M.; Williams, C.; more...
Blood (2018)

Fulltext@MSK | Save

Homebound autologous hematopoietic cell transplantation for plasma cell disorders in an urban setting is safe for patients and preferred by patients and caregivers

Meeting Abstract

Landau, H. J.; Shah, G. L.; Reeds, M.; Hilden, P.; Andrejko, M.; Applebaum, A.; Batalha, J.; Cazeau, N.; Chung, D. J.; Cortes, M.; more...
Blood (2018)

Fulltext@MSK | Save

Comprehensive single-cell RNA-sequencing mapping of primary acute myeloid leukemias and profiling of NPM1-mutated cells

Meeting Abstract

Lavallee, V. P.; Azizi, E.; Kiseliovas, V.; Masilionis, I.; Mazutis, L.; Levine, R. L.; Pe'er, D.
Blood (2018)

Fulltext@MSK | Save

MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone

Meeting Abstract

Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
Blood (2018)

Fulltext@MSK | Save

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

Meeting Abstract

King, A. C.; Pappacena, J.; Tallman, M. S.; Park, J. H.; Geyer, M. B.
Blood (2018)

Fulltext@MSK | Save

Evaluation of combination tagraxofusp (SL-401) and hypomethylating agent (HMA) therapy for the treatment of chronic myelomonocytic leukemia (CMML)

Meeting Abstract

Krishnan, A.; Li, B.; Pagane, M.; McGovern, E.; Stone-Molloy, Z.; Chen, J.; Brooks, C.; Levine, R. L.; Rampal, R. K.
Blood (2018)

Fulltext@MSK | Save

Epigenetic drug treatment induces presentation of new class of non-exonic cryptic neoantigens in acute myeloid leukemia cells

Meeting Abstract

Klatt, M. G.; Mun, S. S.; Socci, N. D.; Korontsvit, T.; Dao, T.; Scheinberg, D. A.
Blood (2018)

Fulltext@MSK | Save

Rivaroxaban thromboprophylaxis in high risk ambulatory cancer patients receiving systemic therapy: Results of a randomized clinical trial (CASSINI)

Meeting Abstract

Khorana, A. A.; Soff, G. A.; Kakkar, A. K.; Vadhan-Raj, S.; Riess, H.; Wun, T.; Streiff, M. B.; Garcia, D. A.; Liebman, H. A.; Belani, C.; more...
Blood (2018)

Fulltext@MSK | Save

Superior clinical benefit of brentuximab vedotin in mycosis fungoides versus physician's choice irrespective of CD30 level or large cell transformation status in the phase 3 ALCANZA study

Meeting Abstract

Kim, Y. H.; Prince, H. M.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Bechter, O.; Sanches, J. A.; Stadler, R.; Scarisbrick, J.; Quaglino, P.; more...
Blood (2018)

Fulltext@MSK | Save